Comparative pharmacoeconomic analysis of rituximab and traditional tacrolimus regimens in membranous nephropathy in China

Comparative pharmacoeconomic analysis of rituximab and traditional tacrolimus regimens in membranous nephropathy in China

Background: Rituximab (RTX) is a monoclonal antibody that selectively targets CD20 and is frequently used in the treatment of membranous nephropathy (MN). Analysis of the therapeutic efficacy and safety of RTX in treating MN in practice and a comparative pharmacoeconomic analysis of the RTX and trad...

Full description

Bibliographic Details
Main Authors: Li Zeng, Huihui Chen, Heng Xiang, Mengru Zeng, Mi Zhou, Chongqing Tan, Hong Liu, Guochun Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Pharmacology
Subjects:
Markov model
membranous nephropathy
pharmacoeconomic analysis
rituximab
tacrolimus
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1309930/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1309930/full

Similar Items